Treatment progress of relapsed/refractory follicular lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 79-81, 2023.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-988956
Responsible library:
WPRO
ABSTRACT
Follicular lymphoma (FL) is the most common indolent B-cell lymphoma. The outcome of relapsed/refractory FL patients after multi-therapy is poor. The 64th American Society of Hematology annual meeting in 2022 announced the latest updates on relapsed/refractory FL, including targeted therapy, bio-specific antibodies and chimeric antigen receptor T-cell. This review provides an overview of these updates.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Leukemia & Lymphoma
Year:
2023
Document type:
Article
